Sunita Sharma
Concepts (317)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 37 | 2025 | 1774 | 6.730 |
Why?
| | Sleep Apnea, Obstructive | 3 | 2025 | 300 | 1.280 |
Why?
| | Gastroesophageal Reflux | 2 | 2023 | 236 | 1.210 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2022 | 919 | 1.020 |
Why?
| | Lung | 16 | 2024 | 4089 | 1.020 |
Why?
| | Adenomyosis | 1 | 2025 | 6 | 0.940 |
Why?
| | Adrenal Cortex Hormones | 3 | 2021 | 480 | 0.930 |
Why?
| | Embryo Implantation | 1 | 2025 | 30 | 0.930 |
Why?
| | Adrenergic beta-Agonists | 2 | 2020 | 92 | 0.910 |
Why?
| | Fertilization in Vitro | 1 | 2025 | 92 | 0.890 |
Why?
| | Genome-Wide Association Study | 8 | 2023 | 1374 | 0.860 |
Why?
| | Genetic Predisposition to Disease | 11 | 2025 | 2350 | 0.830 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2025 | 212 | 0.820 |
Why?
| | Tertiary Care Centers | 1 | 2024 | 194 | 0.770 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2024 | 630 | 0.760 |
Why?
| | Gene Expression Regulation | 3 | 2022 | 2591 | 0.660 |
Why?
| | DNA Methylation | 5 | 2024 | 664 | 0.660 |
Why?
| | Drug Monitoring | 1 | 2024 | 396 | 0.650 |
Why?
| | Smoke | 2 | 2023 | 147 | 0.650 |
Why?
| | Dermatitis, Atopic | 2 | 2024 | 323 | 0.630 |
Why?
| | Antihypertensive Agents | 1 | 2024 | 512 | 0.630 |
Why?
| | GTP Phosphohydrolases | 1 | 2020 | 93 | 0.620 |
Why?
| | Dyspnea | 1 | 2022 | 250 | 0.620 |
Why?
| | Bacteroides fragilis | 2 | 2016 | 14 | 0.610 |
Why?
| | Gene Expression Profiling | 6 | 2016 | 1766 | 0.600 |
Why?
| | MicroRNAs | 3 | 2024 | 689 | 0.600 |
Why?
| | Obesity | 5 | 2025 | 3070 | 0.600 |
Why?
| | Polysaccharides, Bacterial | 2 | 2016 | 69 | 0.580 |
Why?
| | Humans | 63 | 2025 | 144667 | 0.580 |
Why?
| | Epigenesis, Genetic | 3 | 2023 | 669 | 0.580 |
Why?
| | Hypertension | 2 | 2025 | 1262 | 0.580 |
Why?
| | Exercise Test | 1 | 2022 | 626 | 0.570 |
Why?
| | Glucocorticoids | 2 | 2020 | 528 | 0.560 |
Why?
| | Phenotype | 7 | 2025 | 3147 | 0.560 |
Why?
| | Genomics | 3 | 2020 | 831 | 0.550 |
Why?
| | Marijuana Use | 1 | 2022 | 212 | 0.540 |
Why?
| | Polymorphism, Single Nucleotide | 9 | 2023 | 2137 | 0.520 |
Why?
| | Dietary Supplements | 3 | 2019 | 575 | 0.510 |
Why?
| | Biomarkers | 4 | 2025 | 4261 | 0.510 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2018 | 118 | 0.500 |
Why?
| | Biosynthetic Pathways | 1 | 2016 | 25 | 0.500 |
Why?
| | Ascorbic Acid | 1 | 2017 | 171 | 0.470 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 3 | 2024 | 92 | 0.470 |
Why?
| | CD4-Positive T-Lymphocytes | 4 | 2026 | 1129 | 0.460 |
Why?
| | Gene Expression Regulation, Developmental | 4 | 2016 | 906 | 0.450 |
Why?
| | Quantitative Trait Loci | 1 | 2017 | 374 | 0.450 |
Why?
| | Pulmonary Emphysema | 1 | 2017 | 275 | 0.430 |
Why?
| | Cannabis | 1 | 2022 | 509 | 0.430 |
Why?
| | alpha-N-Acetylgalactosaminidase | 1 | 2014 | 1 | 0.430 |
Why?
| | Genes, Developmental | 1 | 2014 | 2 | 0.420 |
Why?
| | Fatty Acid Desaturases | 1 | 2014 | 31 | 0.410 |
Why?
| | Vitamin B Complex | 1 | 2013 | 40 | 0.400 |
Why?
| | Decision Support Systems, Clinical | 1 | 2017 | 269 | 0.390 |
Why?
| | Dexamethasone | 1 | 2015 | 366 | 0.380 |
Why?
| | Genetic Association Studies | 2 | 2011 | 369 | 0.380 |
Why?
| | Food | 1 | 2013 | 148 | 0.370 |
Why?
| | Environmental Exposure | 3 | 2014 | 574 | 0.360 |
Why?
| | Eczema | 2 | 2011 | 66 | 0.360 |
Why?
| | Citrulline | 2 | 2023 | 46 | 0.340 |
Why?
| | Epidemiologic Studies | 1 | 2011 | 68 | 0.330 |
Why?
| | Bronchodilator Agents | 2 | 2023 | 184 | 0.310 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2026 | 915 | 0.290 |
Why?
| | Risk Factors | 10 | 2025 | 10796 | 0.290 |
Why?
| | Pyroglyphidae | 1 | 2008 | 18 | 0.290 |
Why?
| | Wnt Proteins | 1 | 2009 | 133 | 0.280 |
Why?
| | Female | 31 | 2025 | 78304 | 0.280 |
Why?
| | Nepal | 2 | 2025 | 32 | 0.270 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2008 | 176 | 0.260 |
Why?
| | Pregnancy | 8 | 2025 | 7122 | 0.250 |
Why?
| | Male | 28 | 2026 | 72431 | 0.250 |
Why?
| | Placenta | 3 | 2023 | 781 | 0.240 |
Why?
| | Coronary Care Units | 2 | 2016 | 27 | 0.230 |
Why?
| | Glycosyltransferases | 2 | 2016 | 16 | 0.230 |
Why?
| | Government Employees | 1 | 2025 | 2 | 0.230 |
Why?
| | Immunity, Innate | 1 | 2011 | 843 | 0.230 |
Why?
| | Pregnancy Rate | 1 | 2025 | 69 | 0.230 |
Why?
| | Case-Control Studies | 5 | 2024 | 3603 | 0.230 |
Why?
| | Treatment Outcome | 6 | 2025 | 11735 | 0.220 |
Why?
| | Animals | 14 | 2026 | 37948 | 0.220 |
Why?
| | Child | 13 | 2023 | 22600 | 0.220 |
Why?
| | Infertility, Female | 1 | 2025 | 111 | 0.220 |
Why?
| | Lung Diseases | 2 | 2016 | 781 | 0.220 |
Why?
| | Principal Component Analysis | 3 | 2016 | 195 | 0.210 |
Why?
| | Respiratory Function Tests | 2 | 2020 | 541 | 0.210 |
Why?
| | Administration, Inhalation | 2 | 2020 | 570 | 0.210 |
Why?
| | Arteries | 1 | 2026 | 258 | 0.210 |
Why?
| | Health Services for the Aged | 1 | 2024 | 71 | 0.210 |
Why?
| | Quality of Life | 4 | 2025 | 3183 | 0.210 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2024 | 93 | 0.210 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 293 | 0.210 |
Why?
| | Gene Expression | 3 | 2018 | 1476 | 0.200 |
Why?
| | Double-Blind Method | 4 | 2016 | 2033 | 0.190 |
Why?
| | Aorta | 1 | 2026 | 427 | 0.190 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2024 | 97 | 0.190 |
Why?
| | Mendelian Randomization Analysis | 1 | 2023 | 54 | 0.190 |
Why?
| | Health Services Needs and Demand | 1 | 2024 | 276 | 0.190 |
Why?
| | Pregnancy Outcome | 1 | 2025 | 479 | 0.180 |
Why?
| | Life Style | 1 | 2025 | 481 | 0.180 |
Why?
| | Developing Countries | 1 | 2024 | 317 | 0.180 |
Why?
| | Causality | 1 | 2023 | 126 | 0.180 |
Why?
| | Aryldialkylphosphatase | 1 | 2022 | 17 | 0.180 |
Why?
| | Adult | 12 | 2025 | 40489 | 0.180 |
Why?
| | Immunity | 1 | 2022 | 139 | 0.170 |
Why?
| | Health Services | 1 | 2022 | 114 | 0.160 |
Why?
| | Marijuana Smoking | 1 | 2024 | 249 | 0.160 |
Why?
| | Postnatal Care | 1 | 2021 | 76 | 0.160 |
Why?
| | Child, Preschool | 6 | 2023 | 11790 | 0.160 |
Why?
| | Symptom Flare Up | 1 | 2020 | 37 | 0.160 |
Why?
| | Forced Expiratory Volume | 4 | 2019 | 448 | 0.160 |
Why?
| | Inflammation | 2 | 2025 | 2870 | 0.160 |
Why?
| | Menstrual Cycle | 1 | 2021 | 140 | 0.160 |
Why?
| | Genetic Loci | 2 | 2023 | 260 | 0.160 |
Why?
| | Hospitalization | 2 | 2020 | 2446 | 0.160 |
Why?
| | GTPase-Activating Proteins | 1 | 2020 | 81 | 0.160 |
Why?
| | Chemotaxis | 1 | 2020 | 123 | 0.160 |
Why?
| | Smoking | 2 | 2020 | 1467 | 0.150 |
Why?
| | Fetus | 2 | 2016 | 800 | 0.150 |
Why?
| | Severity of Illness Index | 3 | 2020 | 2922 | 0.150 |
Why?
| | RNA, Messenger | 3 | 2024 | 2815 | 0.150 |
Why?
| | Exercise Tolerance | 1 | 2022 | 282 | 0.150 |
Why?
| | Nitric Oxide | 2 | 2026 | 894 | 0.150 |
Why?
| | Neurotoxicity Syndromes | 1 | 2019 | 40 | 0.150 |
Why?
| | Interleukins | 1 | 2020 | 248 | 0.140 |
Why?
| | Vincristine | 1 | 2019 | 140 | 0.140 |
Why?
| | Nedocromil | 2 | 2008 | 20 | 0.140 |
Why?
| | Multigene Family | 2 | 2016 | 210 | 0.140 |
Why?
| | Tenofovir | 2 | 2024 | 295 | 0.140 |
Why?
| | Antiviral Agents | 1 | 2024 | 765 | 0.140 |
Why?
| | Maternal Exposure | 2 | 2017 | 185 | 0.140 |
Why?
| | Malnutrition | 1 | 2019 | 86 | 0.140 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2019 | 176 | 0.140 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5870 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2020 | 267 | 0.140 |
Why?
| | Vital Capacity | 2 | 2009 | 290 | 0.140 |
Why?
| | Administration, Oral | 1 | 2021 | 851 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 990 | 0.130 |
Why?
| | Breast Feeding | 1 | 2022 | 444 | 0.130 |
Why?
| | Prevalence | 2 | 2025 | 2839 | 0.130 |
Why?
| | Particulate Matter | 1 | 2020 | 337 | 0.130 |
Why?
| | Torsades de Pointes | 1 | 2017 | 23 | 0.130 |
Why?
| | Blood Pressure | 1 | 2024 | 1766 | 0.130 |
Why?
| | Databases, Genetic | 2 | 2016 | 247 | 0.130 |
Why?
| | Aldehyde-Ketone Transferases | 1 | 2016 | 1 | 0.130 |
Why?
| | Acetylgalactosamine | 1 | 2016 | 2 | 0.130 |
Why?
| | Electrocardiography | 2 | 2017 | 664 | 0.130 |
Why?
| | Air Pollution | 1 | 2020 | 318 | 0.120 |
Why?
| | Histones | 1 | 2022 | 663 | 0.120 |
Why?
| | Arginine | 3 | 2023 | 238 | 0.120 |
Why?
| | Comorbidity | 1 | 2021 | 1652 | 0.120 |
Why?
| | Long QT Syndrome | 1 | 2017 | 69 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1501 | 0.120 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 293 | 0.120 |
Why?
| | Vitamins | 1 | 2017 | 176 | 0.120 |
Why?
| | Magnesium | 1 | 2016 | 155 | 0.120 |
Why?
| | Folic Acid | 1 | 2017 | 198 | 0.120 |
Why?
| | Betamethasone | 1 | 2015 | 21 | 0.120 |
Why?
| | Middle Aged | 8 | 2025 | 35971 | 0.110 |
Why?
| | CCAAT-Enhancer-Binding Protein-delta | 1 | 2015 | 6 | 0.110 |
Why?
| | Cyclohexanes | 1 | 2015 | 23 | 0.110 |
Why?
| | Cadherins | 1 | 2017 | 200 | 0.110 |
Why?
| | Aged | 7 | 2024 | 25955 | 0.110 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2015 | 25 | 0.110 |
Why?
| | Aging | 1 | 2026 | 1938 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2016 | 751 | 0.110 |
Why?
| | Gels | 1 | 2015 | 85 | 0.110 |
Why?
| | Animals, Newborn | 2 | 2015 | 890 | 0.110 |
Why?
| | Neutrophils | 1 | 2020 | 1118 | 0.110 |
Why?
| | Disease Transmission, Infectious | 1 | 2015 | 68 | 0.110 |
Why?
| | Lung Neoplasms | 2 | 2021 | 2660 | 0.110 |
Why?
| | Hospital Mortality | 2 | 2016 | 1033 | 0.110 |
Why?
| | Arrhythmias, Cardiac | 1 | 2017 | 355 | 0.110 |
Why?
| | Costa Rica | 1 | 2014 | 18 | 0.110 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2015 | 106 | 0.110 |
Why?
| | Disulfiram | 1 | 2014 | 15 | 0.100 |
Why?
| | Genetic Markers | 1 | 2015 | 332 | 0.100 |
Why?
| | Delirium | 1 | 2015 | 105 | 0.100 |
Why?
| | Triazoles | 1 | 2015 | 184 | 0.100 |
Why?
| | Mesothelioma | 1 | 2014 | 50 | 0.100 |
Why?
| | Mice, Inbred C57BL | 4 | 2026 | 5967 | 0.100 |
Why?
| | Forecasting | 1 | 2015 | 391 | 0.100 |
Why?
| | Myocardial Ischemia | 1 | 2015 | 285 | 0.100 |
Why?
| | Ornithine | 2 | 2023 | 17 | 0.100 |
Why?
| | Antipsychotic Agents | 1 | 2015 | 214 | 0.100 |
Why?
| | Genome, Bacterial | 1 | 2014 | 158 | 0.100 |
Why?
| | Gestational Age | 3 | 2012 | 980 | 0.090 |
Why?
| | Cotinine | 1 | 2012 | 76 | 0.090 |
Why?
| | Cohort Studies | 4 | 2017 | 5957 | 0.090 |
Why?
| | Epigenomics | 2 | 2023 | 112 | 0.090 |
Why?
| | Maternal Behavior | 1 | 2012 | 83 | 0.090 |
Why?
| | Acetyl-CoA C-Acyltransferase | 1 | 2011 | 2 | 0.090 |
Why?
| | Nicotine | 1 | 2014 | 334 | 0.090 |
Why?
| | Morbidity | 2 | 2023 | 322 | 0.090 |
Why?
| | Premature Birth | 1 | 2015 | 376 | 0.090 |
Why?
| | Signal Transduction | 3 | 2020 | 5185 | 0.080 |
Why?
| | Prospective Studies | 5 | 2024 | 7994 | 0.080 |
Why?
| | Alleles | 2 | 2017 | 886 | 0.080 |
Why?
| | Endotoxins | 1 | 2011 | 218 | 0.080 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 641 | 0.080 |
Why?
| | Adolescent | 5 | 2024 | 22409 | 0.080 |
Why?
| | Sex Characteristics | 1 | 2016 | 776 | 0.080 |
Why?
| | Intestines | 1 | 2013 | 357 | 0.080 |
Why?
| | Mice | 6 | 2026 | 18261 | 0.080 |
Why?
| | Vitamin D | 1 | 2013 | 400 | 0.080 |
Why?
| | Bayes Theorem | 1 | 2011 | 426 | 0.080 |
Why?
| | Transcriptome | 1 | 2016 | 1036 | 0.070 |
Why?
| | Computational Biology | 1 | 2013 | 681 | 0.070 |
Why?
| | Macaca | 2 | 2021 | 65 | 0.070 |
Why?
| | Budesonide | 1 | 2008 | 49 | 0.070 |
Why?
| | Infant, Newborn | 2 | 2017 | 6399 | 0.070 |
Why?
| | Bronchial Hyperreactivity | 1 | 2008 | 96 | 0.070 |
Why?
| | Spirometry | 1 | 2008 | 231 | 0.070 |
Why?
| | Young Adult | 5 | 2025 | 14122 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2015 | 890 | 0.070 |
Why?
| | United States | 3 | 2021 | 16018 | 0.060 |
Why?
| | Bacterial Proteins | 1 | 2014 | 981 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1537 | 0.060 |
Why?
| | Transcription Factors | 1 | 2015 | 1726 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2014 | 2489 | 0.060 |
Why?
| | Anti-Asthmatic Agents | 1 | 2008 | 253 | 0.060 |
Why?
| | Microbiota | 1 | 2013 | 782 | 0.060 |
Why?
| | Allergens | 1 | 2008 | 387 | 0.060 |
Why?
| | Apoptosis | 1 | 2014 | 2397 | 0.060 |
Why?
| | Autopsy | 1 | 2005 | 94 | 0.060 |
Why?
| | Diketopiperazines | 1 | 2024 | 22 | 0.050 |
Why?
| | Altruism | 1 | 2024 | 27 | 0.050 |
Why?
| | Pteridines | 1 | 2024 | 22 | 0.050 |
Why?
| | Dietary Sugars | 1 | 2024 | 16 | 0.050 |
Why?
| | Interleukin-5 | 1 | 2024 | 39 | 0.050 |
Why?
| | Macaca mulatta | 1 | 2024 | 186 | 0.050 |
Why?
| | Oxidative Stress | 2 | 2022 | 1338 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2015 | 5414 | 0.050 |
Why?
| | Algorithms | 1 | 2011 | 1844 | 0.050 |
Why?
| | Viremia | 1 | 2024 | 159 | 0.050 |
Why?
| | Emergencies | 1 | 2024 | 175 | 0.050 |
Why?
| | Albuterol | 1 | 2023 | 73 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 179 | 0.050 |
Why?
| | Emtricitabine | 1 | 2024 | 205 | 0.050 |
Why?
| | Pyridones | 1 | 2024 | 201 | 0.050 |
Why?
| | Vasodilation | 1 | 2026 | 520 | 0.050 |
Why?
| | Viral Load | 1 | 2024 | 528 | 0.050 |
Why?
| | Quercetin | 1 | 2022 | 19 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 6041 | 0.040 |
Why?
| | England | 1 | 2022 | 108 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 184 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2022 | 122 | 0.040 |
Why?
| | Fibroblast Growth Factors | 1 | 2023 | 188 | 0.040 |
Why?
| | Receptors, CCR5 | 1 | 2021 | 60 | 0.040 |
Why?
| | Vascular Stiffness | 1 | 2026 | 485 | 0.040 |
Why?
| | Poverty | 1 | 2024 | 522 | 0.040 |
Why?
| | Incidence | 2 | 2019 | 2892 | 0.040 |
Why?
| | Hydrogen Peroxide | 1 | 2022 | 334 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2024 | 672 | 0.040 |
Why?
| | Progesterone | 1 | 2021 | 209 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2019 | 88 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 342 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2019 | 161 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2026 | 949 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2022 | 638 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2021 | 572 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 323 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2023 | 1106 | 0.030 |
Why?
| | Netherlands | 1 | 2016 | 82 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2847 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 472 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2024 | 1098 | 0.030 |
Why?
| | Demography | 1 | 2017 | 287 | 0.030 |
Why?
| | Vaccination | 1 | 2024 | 1419 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2020 | 710 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2114 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 284 | 0.030 |
Why?
| | Administration, Topical | 1 | 2015 | 152 | 0.030 |
Why?
| | Placebos | 1 | 2015 | 193 | 0.030 |
Why?
| | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2014 | 6 | 0.030 |
Why?
| | Uridine Diphosphate | 1 | 2014 | 4 | 0.030 |
Why?
| | Death, Sudden, Cardiac | 1 | 2016 | 230 | 0.030 |
Why?
| | Bacterial Capsules | 1 | 2014 | 33 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 915 | 0.030 |
Why?
| | Galactose | 1 | 2014 | 32 | 0.030 |
Why?
| | Terpenes | 1 | 2014 | 25 | 0.030 |
Why?
| | CpG Islands | 1 | 2014 | 161 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 1886 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2016 | 17149 | 0.020 |
Why?
| | Caspase 3 | 1 | 2014 | 234 | 0.020 |
Why?
| | Cytochrome P-450 CYP1B1 | 1 | 2012 | 5 | 0.020 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2012 | 9 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2012 | 88 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2015 | 605 | 0.020 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 45 | 0.020 |
Why?
| | Exercise | 1 | 2024 | 2183 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2419 | 0.020 |
Why?
| | Infant | 2 | 2019 | 10023 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2011 | 249 | 0.020 |
Why?
| | Models, Animal | 1 | 2012 | 393 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2014 | 441 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2014 | 1363 | 0.020 |
Why?
| | ROC Curve | 1 | 2012 | 618 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 973 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 481 | 0.020 |
Why?
| | NF-kappa B | 1 | 2014 | 657 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 2011 | 315 | 0.020 |
Why?
| | Up-Regulation | 1 | 2012 | 848 | 0.020 |
Why?
| | Escherichia coli | 1 | 2014 | 854 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2942 | 0.020 |
Why?
| | Linear Models | 1 | 2011 | 845 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 3329 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 1076 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2011 | 854 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 8284 | 0.020 |
Why?
| | Cell Line | 1 | 2013 | 2821 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1437 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1995 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2117 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1847 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3523 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2015 | 4539 | 0.010 |
Why?
| | Liver | 1 | 2012 | 1889 | 0.010 |
Why?
| | Risk Assessment | 1 | 2011 | 3729 | 0.010 |
Why?
|
|
Sharma's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|